Risk Assessment and Management of Massive Upper Gastrointestinal Bleeding

Medication‑Related Risk Factors

A history of a prior upper gastrointestinal bleed is the single strongest predictor of future massive bleeding events. 1
Use of multiple antithrombotic agents (combined anticoagulants and antiplatelet drugs) dramatically raises the risk of massive upper GI hemorrhage. 1
Regular NSAID or aspirin intake together with additional risk enhancers (e.g., age > 60 years, corticosteroid use, anticoagulation, or severe comorbidities) markedly increases bleeding risk. 4
Dual antiplatelet therapy (e.g., aspirin + clopidogrel) is associated with a higher likelihood of massive upper GI bleeding. 1

Age > 60 years independently predicts higher mortality and more severe bleeding when massive upper GI hemorrhage occurs. 5
Severe comorbid conditions—including cardiac disease, renal failure, liver disease/cirrhosis, or disseminated malignancy—significantly elevate the risk of massive bleeding. 6
Helicobacter pylori infection in patients with peptic ulcer disease increases the probability of massive upper GI bleeding. 1
Cirrhosis with portal hypertension creates a high risk for variceal hemorrhage, a common cause of massive upper GI bleeding. 2

Nausea or mild upper‑abdominal discomfort may precede ulcer perforation or erosion into a vessel, heralding a potential massive bleed. 2
Repeated vomiting (e.g., in the setting of diabetic ketoacidosis or thyroid storm) can precipitate Mallory‑Weiss tears or stress‑related mucosal disease, leading to massive hemorrhage. 2

Stress‑related mucosal disease in critically ill patients can develop rapidly and present as massive bleeding without a prodrome. 2
Dieulafoy’s lesion (a tortuous submucosal artery) typically causes sudden massive hemorrhage without prior symptoms. 2
Variceal bleeding in cirrhotic patients may occur abruptly despite known varices. 2
Although bleeding stops spontaneously in 75‑90 % of upper GI bleeds, overall mortality remains 2‑14 %, underscoring that cessation of bleeding does not guarantee low risk. 6

Shock (heart rate > 100 bpm and systolic blood pressure < 100 mmHg) combined with active arterial bleeding from a peptic ulcer predicts an ~80 % chance of continued bleeding or death. 5
Endoscopic observation of active arterial spurting or oozing predicts a 50‑80 % risk of death. 5

Systematically screen all patients for the above risk factors during routine care, emphasizing a detailed medication history that includes over‑the‑counter NSAIDs and aspirin. 1
Test for H. pylori infection in patients with dyspepsia who are on chronic NSAID therapy. 1
Provide proton‑pump inhibitor (PPI) gastroprotection for high‑risk individuals (those with prior bleeding, multiple antithrombotics, or NSAID use plus additional risk factors). 4
Avoid de‑prescribing PPIs in patients with a history of upper GI bleeding or multiple bleeding risk factors. 1
In patients aged > 90 years, mortality from massive upper GI bleeding can reach 30 %; aggressive modification of modifiable risk factors is essential. 6